Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00585962
Recruitment Status :
First Posted : January 4, 2008
Last Update Posted : September 5, 2017
Massachusetts General Hospital
American College of Radiology Imaging Network
Information provided by (Responsible Party):
Anthony Laurence Zietman, MD, Massachusetts General Hospital
The primary purpose of this study is to determine if high doses of radiation using proton beam can be given safely with low and acceptable side effects. This study will also gather data to determine the ability of the proton beam to eradicate prostate cancer. Proton beam radiation is a very accurate kind of treatment that has been shown to affect less normal tissue than a regular radiation beam.
Condition or disease
Radiation: Proton Beam Radiation
Radiation therapy to the pelvis and prostate will be given once a day, 5 days a week (Monday-Friday), for 8 weeks. Each treatment takes about 10-20 minutes.
Participants will be seen once a week for the entire 8 weeks by their study doctor to monitor and record any side effects. At the end of radiation therapy, participants will have a history and physical examination. Follow-up visits with the study doctor will be done at weeks 13 and 26 and then every 6 months for 3 years, then annually to year five.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with previously treated adenocarcinoma of the stages T1c-T2b and Gleason of equal to or greater than 5.
PSA values of equal to or less than 15 ng/ml must be demonstrated within two months prior to study entry and greater than 3 weeks after prostate biopsy.
Zubrod status 0-1.
No evidence of distant metastasis.
No evidence of other cancer. Prior malignancy does not exclude the patient if disease free for greater than five years.
Clinical stages T2c or above.
PSA greater than 15.
Any patient with T1c disease, a PSA less than or equal to 4 and Gleason sum less than 6.
Evidence of lymph node involvement if lymph node sampling performed.
Previous prostate surgery to include: simple prostatectomy, TURP, hyperthermia and cryosurgery.
Previous prostate radiation.
Prior hormonal therapy.
History of inflammatory bowel disease even if currently inactive or controlled on medication.
Prior systemic chemotherapy.
History of proximal urethral stricture requiring dilatation.
Current and continuing anticoagulation with Coumadin or equivalent.